Trial Profile
A Compassionate Use Study of Namilumab (IZN-101) in the Treatment of Patients with Rapidly Worsening COVID-19
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 07 Apr 2020
Price :
$35
*
At a glance
- Drugs Namilumab (Primary)
- Indications COVID 2019 infections
- Focus Expanded access; Therapeutic Use
- 07 Apr 2020 New trial record
- 06 Apr 2020 According to an Ergomed media release, the team working with Prof. Selmi will be coordinated locally by Dr. Amidio Testa and Dr. Giacomo Guidelli.
- 06 Apr 2020 According to an Izana Bioscience media release, Ergomed plc, a CRO specialised in providing bespoke solutions and research services to the company, is facilitating this programme.